创新药又有新药获批，关注创新药ETF国泰（517110）

Group 1 - The core viewpoint of the news highlights significant advancements in innovative drug companies, particularly the approval of new drugs by regulatory authorities, indicating a positive trend in the sector [1][2] - DiZhe Pharmaceutical's new drug, Shuwozhe, has received FDA approval for treating advanced non-small cell lung cancer, marking it as China's first independently developed innovative drug approved in the U.S. [1] - The National Healthcare Security Administration has introduced guidelines for adjusting the commercial health insurance innovative drug directory, which will include drugs with significant clinical value that exceed basic insurance coverage [2] Group 2 - The innovative drug sector has shown impressive growth in the first half of 2025, although it is currently experiencing a short-term adjustment [2] - China's innovative drug industry is transitioning from "importing and imitating" to "innovative output," enhancing its international competitiveness [2] - The innovative drug ETF Guotai (517110) has performed well, gaining 2.80% on July 3, indicating strong market interest in this sector [3][4]